Welbreth Tablet SR is a sustained-release formulation combining Ambroxol 75mg, Levocetirizine 5mg, and Montelukast 10mg, designed to provide comprehensive management of respiratory conditions characterized by cough, allergic rhinitis, and bronchial asthma. Ambroxol, a mucolytic agent, facilitates the breakdown and clearance of mucus by enhancing mucociliary transport and stimulating surfactant production, thereby improving airway patency. Levocetirizine, a selective second-generation antihistamine, effectively alleviates symptoms of allergic rhinitis such as sneezing, nasal congestion, and rhinorrhea by blocking peripheral H1 histamine receptors with minimal sedative effects. Montelukast, a leukotriene receptor antagonist, inhibits cysteinyl leukotriene receptors, reducing bronchoconstriction, inflammation, and mucus secretion associated with asthma and allergic rhinitis. The sustained-release mechanism ensures prolonged therapeutic plasma concentrations, promoting once-daily dosing and improved patient compliance. Welbreth Tablet SR is indicated for the symptomatic relief of chronic respiratory disorders involving mucus hypersecretion, allergic manifestations, and bronchospasm. It should be used under medical supervision, considering contraindications such as hypersensitivity to any component. Common adverse effects may include gastrointestinal discomfort, headache, and mild sedation. This combination therapy offers a synergistic approach to managing complex respiratory conditions by targeting multiple pathophysiological pathways.